News >

Bendamustine Plus Rituximab Maintains Frontline PFS Benefit in MCL, iNHL After 5 Years

Jason Harris
Published: Monday, Jul 17, 2017

Ian W. Flinn, MD, PhD

Ian W. Flinn, MD, PhD

Five-year follow-up from the BRIGHT study confirmed that bendamustine plus rituximab (BR) is associated with improved progression-free survival (PFS) compared with R-CHOP or R-CVP in patients with mantle cell lymphoma (MCL) or indolent non-Hodgkin lymphoma (iNHL).

Patients in the BR group were more likely to experience squamous cell carcinoma (12 vs 2) and basal cell carcinoma (9 vs 4), as well as other solid tumors (19 vs 11).
Flinn I, van der Jagt R, Chang JE, et al. First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study. J Clin Oncol 35, 2017 (suppl; abstr 7500).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication